Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 3Gynecologic 2CNS 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Hypoxia 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Circulating Tumor DNA × Genitourinary × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06537154 2025-07-30

NEO-BLAST

University of British Columbia

Phase 2/3 Recruiting
688 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05702619 2023-01-27

HYPROGEN

The Christie NHS Foundation Trust

Unknown
60 enrolled
Genitourinary

Hypoxia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡